Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 42 clinical trials
Dolutegravir-Lamivudine for na ve HIV-Infected Patients With 200 CD4/mm3

Protocol Title: DOLCE: Dolutegravir-Lamivudine for nave HIV-Infected Patients with 200 CD4/mm3 Protocol Number: FH-57 Study Objectives: To assess the antiviral activity at week 48

  • 0 views
  • 04 Oct, 2021
  • 4 locations
Dolutegravir Study in HIV-1 Participants Completing IMPAACT Studies P1093 and P2019

Dolutegravir is a potent integrase strand transfer inhibitor. Abacavir/dolutegravir/lamivudine (ABC/DTG/3TC) is a fixed dose combination regimen containing two nucleoside reverse transcriptase

dolutegravir
lamivudine
integrase inhibitors
immunodeficiency
reverse transcriptase inhibitor
  • 188 views
  • 23 Mar, 2022
  • 15 locations
A Clinical Trial of GSK3640254 + Dolutegravir (DTG) in Human Immunodeficiency Virus-1 Infected Treatment-naive Adults (DYNAMIC)

The purpose of this study is to evaluate the efficacy of GSK3640254 + DTG relative to lamivudine (3TC) + DTG in treatment-naïve adult participants living with human immunodeficiency virus (HIV)-1. The participants will be randomized to one of the three doses of blinded GSK3640254 (100, 150, or 200 milligrams [mgs]) …

dolutegravir
lamivudine
body mass index
HIV Vaccine
immunodeficiency
  • 0 views
  • 14 May, 2022
  • 55 locations
Drug-Drug Interactions Between Rifapentine and Dolutegravir in HIV/LTBI Co-Infected Individuals

This study will evaluate the potential drug-drug interactions between dolutegravir (DTG) and steady state rifapentine (RPT) when RPT is given with isoniazid (INH) daily for 4 weeks (1HP) as part

rifapentine
dolutegravir
hysterectomy
chest radiograph
antibody test
  • 20 views
  • 02 May, 2022
  • 10 locations
Body Composition Sub-study of the D2EFT Trial

This is a non-randomised, controlled, parallel group, sub-study of D2EFT (NCT03017872), a randomised, open-label study in approximately 1,000 HIV-infected adults failing first-line antiretroviral therapy (ART) in low-middle income countries. The sub-study will be offered to all D2EFT sites with access to DXA technology for whole-body composition analysis. Sites will offer …

emtricitabine
darunavir
dolutegravir
lamivudine
ritonavir
  • 9 views
  • 21 Feb, 2022
  • 7 locations
Tuberculosis Preventive Therapy Among Latent Tuberculosis Infection in HIV-infected Individuals

The investigators want to know if ultra-short, effective treatment for latent tuberculosis (TB) infection (LTBI) could dramatically reduce the global incidence of active TB or not. The investigators hypothesize that short-course (4-week) daily isoniazid/rifapentine (INH/RPT) (1HP) is not inferior to standard -course (12 weeks) INH/RPT weekly regimen (3HP) for the …

  • 0 views
  • 13 Apr, 2022
  • 1 location
Determination of Adequate Tuberculosis Regimen in Patients Hospitalized With HIV-associated Severe Immune Suppression (DATURA)

DATURA trial is a phase III, multicenter, two-arm, open-label, randomized superiority trial to compare the efficacy and the safety of an intensified tuberculosis (TB) regimen versus standard TB treatment in HIV-infected adults and adolescents hospitalized for TB with CD4 ≤ 100 cells/μL over 48 weeks: Intensified TB treatment regimen: increased …

  • 0 views
  • 11 May, 2022
Early DOlutegravir/LAmivudine Switching After Virological Suppression (EDOLAS Study)

Phase III, randomized, open-label, multicentre, active-controlled, non-inferiority study evaluating the efficacy and safety of early switching to dolutegravir/lamivudine (DTG/3TC) in single-pill

  • 0 views
  • 05 Aug, 2021
  • 23 locations
Effect of Dolutegravir Intensification on HIV-1 Reservoirs (EDIT)

replication to HIV persistence under ART by undertaking a treatment intensification trial with high-dose dolutegravir. Tissue/blood samples and replication-competent reservoir measurements will be included

  • 0 views
  • 17 May, 2022
  • 1 location
Drug Interactions Between Dolutegravir and Escalating Doses of Rifampicin (DoRIS)

This is a drug interaction study in HIV negative, TB-monoinfected participants coming to the end of continuation phase of TB therapy, to study the pharmacokinetic changes to dolutegravir when

  • 0 views
  • 04 Jun, 2022
  • 1 location